{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T06:01:31Z","timestamp":1790661691668,"version":"4.1.0"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T00:00:00Z","timestamp":1784937600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010877","name":"ViiV Healthcare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010877","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Poppy Mashilo"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Long-acting cabotegravir plus rilpivirine (CAB+RPV LA) and dolutegravir plus lamivudine (DTG\/3TC) are HIV-1 antiretroviral therapy regimens with different administration routes and dosing frequencies, allowing for greater choice.plus<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>VOLITION is a phase 3b, multicenter, nonrandomized, parallel-group, open-label implementation\u2013effectiveness study (NCT05917509) evaluating viral suppression on DTG\/3TC for up to 16 weeks, followed by a participant-determined optional switch to CAB+RPV LA dosed Q2M or continuation of DTG\/3TC through Month (M) 11\/12. Co-primary endpoints were the time to virologic suppression with DTG\/3TC and the proportion of participants with HIV RNA &amp;lt; 50\u2005copies\/mL per the Snapshot algorithm at M11 with CAB+RPV LA. Safety and participant experience were also assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>One hundred and seventy-one participants initiated DTG\/3TC. Median time to suppression on DTG\/3TC was 4.1 weeks (95% confidence interval: 4.1\u20134.3), with 98% (n = 167\/171) achieving virologic suppression and similar rates observed across baseline viral load and CD4+ cell count categories. At Day of Choice (DoC), 85% (n = 129\/151) of eligible participants chose to switch to CAB+RPV LA. At M11, 113\/129 (88%) participants maintained suppression with CAB+RPV LA; 1 participant had confirmed virologic failure with resistance (integrase strand transfer inhibitor and non-nucleoside reverse transcriptase inhibitor). Both regimens were well tolerated, with no new safety signals observed. Treatment satisfaction improved after DoC and remained high with CAB+RPV LA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Providing treatment-naive participants with the option to switch to CAB+RPV LA as soon as virologic suppression was achieved on daily oral therapy allowed them to choose a treatment to meet their individualized needs while maintaining virologic suppression, which is essential for long-term treatment success and optimized quality of life.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical Trial Registration<\/jats:title>\n                    <jats:p>NCT05917509.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ofid\/ofag383","type":"journal-article","created":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T11:26:17Z","timestamp":1783337177000},"source":"Crossref","is-referenced-by-count":0,"title":["Rapid Virologic Suppression With Dolutegravir Plus Lamivudine Facilitates Early Switch to Long-Acting Cabotegravir Plus Rilpivirine for Treatment-Naive People With HIV-1: Month 11\/12 Outcomes From the Phase 3b VOLITION Study"],"prefix":"10.1093","volume":"13","author":[{"given":"Ezequiel","family":"C\u00f3rdova","sequence":"first","affiliation":[{"name":"IDEAA Foundation , Buenos Aires ,","place":["Argentina"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6444-2225","authenticated-orcid":false,"given":"Charlotte-Paige","family":"Rolle","sequence":"additional","affiliation":[{"name":"Orlando Immunology Center , Orlando, Florida ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Hove","sequence":"additional","affiliation":[{"name":"ViiV Healthcare , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3449-7233","authenticated-orcid":false,"given":"Franco","family":"Felizarta","sequence":"additional","affiliation":[{"name":"Private Practice , Bakersfield, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Johnson","sequence":"additional","affiliation":[{"name":"Atrium Health Carolinas Medical Center , Charlotte, North Carolina ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Cuevas Tasc\u00f3n","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Hospital Universitario Infanta Leonor , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Michel","family":"Molina","sequence":"additional","affiliation":[{"name":"Paris Cit\u00e9 University , INSERM UMR1342 Biology and Pathogenesis of Viral Infections, IRSL, Paris ,","place":["France"]},{"name":"Department of Infectious Diseases, St-Louis and Lariboisi\u00e8re Hospitals, Assistance Publique Hopitaux de Paris , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaquin","family":"Bravo Urbieta","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Internal Medicine Department, Morales Meseguer General University Hospital , Murcia ,","place":["Spain"]},{"name":"Infectious Diseases and Artificial Intelligence Group, Biomedical Research Institute of Murcia Pascual Parrilla-IMIB , Murcia ,","place":["Spain"]},{"name":"Department of Internal Medicine, Faculty of Medicine, University of Murcia , Murcia ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2264-4822","authenticated-orcid":false,"given":"Laurent","family":"Hocqueloux","sequence":"additional","affiliation":[{"name":"Centre Hospitalier Universitaire D\u2019Orl\u00e9ans , Orl\u00e9ans ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Lupo","sequence":"additional","affiliation":[{"name":"Instituto Centralizado de Asistencia e Investigaci\u00f3n Clinica Integral , Rosario ,","place":["Argentina"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos M","family":"Perez","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Universidad San Sebasti\u00e1n , Concepci\u00f3n ,","place":["Chile"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f6rn-Erik","family":"Ole Jensen","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hepatology, and Infectious Diseases, Medical Faculty and University Hospital D\u00fcsseldorf, Heinrich Heine University , D\u00fcsseldorf ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celia","family":"Jonsson-Oldenb\u00fcttel","sequence":"additional","affiliation":[{"name":"MVZ M\u00fcnchen am Goetheplatz , Munich ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco Xavier","family":"Zamora Vargas","sequence":"additional","affiliation":[{"name":"Espacio Eme , Santiago Metropolitan Region ,","place":["Chile"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Szabo","sequence":"additional","affiliation":[{"name":"Clinical Department, L\u2019Actuel Medical Clinic , Montreal, Quebec ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9381-1931","authenticated-orcid":false,"given":"Pedro","family":"Cahn","sequence":"additional","affiliation":[{"name":"Fundaci\u00f3n Hu\u00e9sped , Buenos Aires ,","place":["Argentina"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2121-4684","authenticated-orcid":false,"given":"Andrea","family":"Antinori","sequence":"additional","affiliation":[{"name":"Clinical Infectious Diseases Department, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS , Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Carlos","family":"L\u00f3pez Bernaldo de Quir\u00f3s","sequence":"additional","affiliation":[{"name":"Hospital General Universitario Gregorio Mara\u00f1\u00f3n, IiSGM, CIBERINFEC , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Castagna","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, IRCCS, San Raffaele Scientific Institute , Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Bui","sequence":"additional","affiliation":[{"name":"GSK , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Grove","sequence":"additional","affiliation":[{"name":"GSK , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kehui","family":"Wang","sequence":"additional","affiliation":[{"name":"GSK , Collegeville, Pennsylvania ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marty","family":"St Clair","sequence":"additional","affiliation":[{"name":"ViiV Healthcare , Durham, North Carolina ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riya","family":"Moodley","sequence":"additional","affiliation":[{"name":"ViiV Healthcare , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Radford","sequence":"additional","affiliation":[{"name":"ViiV Healthcare , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Priest","sequence":"additional","affiliation":[{"name":"ViiV Healthcare , Durham, North Carolina ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cassidy A","family":"Gutner","sequence":"additional","affiliation":[{"name":"ViiV Healthcare , Durham, North Carolina ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Jacob","sequence":"additional","affiliation":[{"name":"ViiV Healthcare , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avishek","family":"Chatterjee","sequence":"additional","affiliation":[{"name":"GSK , Bengaluru, Karnataka ,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suryakant","family":"Somvanshi","sequence":"additional","affiliation":[{"name":"GSK , Pune, Maharashtra ,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Kolobova","sequence":"additional","affiliation":[{"name":"ViiV Healthcare , Durham, North Carolina ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rekha","family":"Trehan","sequence":"additional","affiliation":[{"name":"ViiV Healthcare , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Polk","sequence":"additional","affiliation":[{"name":"ViiV Healthcare , Durham, North Carolina ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parul","family":"Patel","sequence":"additional","affiliation":[{"name":"ViiV Healthcare , Durham, North Carolina ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"de los Rios","sequence":"additional","affiliation":[{"name":"ViiV Healthcare , Durham, North Carolina ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"DiMondi","sequence":"additional","affiliation":[{"name":"GSK , Durham, North Carolina ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lori A","family":"Gordon","sequence":"additional","affiliation":[{"name":"ViiV Healthcare , Durham, North Carolina ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberley","family":"Brown","sequence":"additional","affiliation":[{"name":"ViiV Healthcare , Durham, North Carolina ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harmony P","family":"Garges","sequence":"additional","affiliation":[{"name":"ViiV Healthcare , Durham, North Carolina ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryn","family":"Jones","sequence":"additional","affiliation":[{"name":"ViiV Healthcare , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"van Wyk","sequence":"additional","affiliation":[{"name":"ViiV Healthcare , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,7,25]]},"reference":[{"key":"2026092901212647100_ofag383-B1","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1007\/s10461-020-02973-4","article-title":"Shared decision making between patients and healthcare providers and its association with favorable health outcomes among people living with HIV","volume":"25","author":"Okoli","year":"2021","journal-title":"AIDS Behav"},{"key":"2026092901212647100_ofag383-B2","author":"Patel"},{"key":"2026092901212647100_ofag383-B3","doi-asserted-by":"crossref","first-page":"108408","DOI":"10.1016\/j.pec.2024.108408","article-title":"The effects of shared decision making on health outcomes, health care quality, cost, and consultation time: an umbrella review","volume":"129","author":"Bruch","year":"2024","journal-title":"Patient Educ Couns"},{"key":"2026092901212647100_ofag383-B4","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jana.2016.08.010","article-title":"Patients\u2019 perceptions and experiences of shared decision-making in primary HIV care clinics","volume":"28","author":"Fuller","year":"2017","journal-title":"J Assoc Nurses AIDS Care"},{"key":"2026092901212647100_ofag383-B5","author":"Devonald"},{"key":"2026092901212647100_ofag383-B6","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1007\/s10461-020-03055-1","article-title":"Physical, emotional, and psychosocial challenges associated with daily dosing of HIV medications and their impact on indicators of quality of life: findings from the positive perspectives study","volume":"25","author":"de Los Rios","year":"2021","journal-title":"AIDS Behav"},{"key":"2026092901212647100_ofag383-B7","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1007\/s10461-022-03865-5","article-title":"The influence of anticipated HIV stigma on health-related behaviors, self-rated health, and treatment preferences among people living with HIV in East Asia","volume":"27","author":"Yu","year":"2023","journal-title":"AIDS Behav"},{"key":"2026092901212647100_ofag383-B8","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1007\/s10461-024-04490-0","article-title":"Improvements in patient-reported outcomes after 12 months of maintenance therapy with cabotegravir + rilpivirine long-acting compared with bictegravir\/emtricitabine\/tenofovir alafenamide in the phase 3b SOLAR study","volume":"29","author":"Mussini","year":"2025","journal-title":"AIDS Behav"},{"key":"2026092901212647100_ofag383-B9","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s40121-024-00950-1","article-title":"Real-world effectiveness of dolutegravir\/lamivudine in people with HIV-1 in test-and-treat settings or with high baseline viral loads: TANDEM study subgroup analyses","volume":"13","author":"Benson","year":"2024","journal-title":"Infect Dis Ther"},{"key":"2026092901212647100_ofag383-B10","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/QAD.0000000000003070","article-title":"Three-year durable efficacy of dolutegravir plus lamivudine in antiretroviral therapy\u2014naive adults with HIV-1 infection","volume":"36","author":"Cahn","year":"2022","journal-title":"AIDS"},{"key":"2026092901212647100_ofag383-B11","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1186\/s12879-024-09624-2","article-title":"DTG + 3TC dual therapy for the treatment naive patients with viral load exceeding 500,000 copies\/mL: a retrospective study","volume":"24","author":"Dou","year":"2024","journal-title":"BMC Infect Dis"},{"key":"2026092901212647100_ofag383-B12","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/hiv.13699","article-title":"Real-world effectiveness and safety of switching to dolutegravir\/lamivudine among people living with HIV-1 aged over 50 years who are virologically suppressed","volume":"26","author":"Pi\u00f1eiro","year":"2025","journal-title":"HIV Med"},{"key":"2026092901212647100_ofag383-B13","author":"Letang"},{"key":"2026092901212647100_ofag383-B14","author":"British HIV Association"},{"key":"2026092901212647100_ofag383-B15","author":"European AIDS Clinical Society (EACS)"},{"key":"2026092901212647100_ofag383-B16","author":"U.S. Department of Health and Human Services"},{"key":"2026092901212647100_ofag383-B17","author":"European Medicines Agency"},{"key":"2026092901212647100_ofag383-B18","author":"European Medicines Agency"},{"key":"2026092901212647100_ofag383-B19","author":"ViiV Healthcare"},{"key":"2026092901212647100_ofag383-B20","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1111\/hiv.13647","article-title":"Real-world use of long-acting cabotegravir and rilpivirine: 12-month results of the inJectable antiretroviral therapy feasiBility Study (JABS)","volume":"25","author":"John","year":"2024","journal-title":"HIV Med"},{"key":"2026092901212647100_ofag383-B21","author":"Jonsson-Oldenb\u00fcttel"},{"key":"2026092901212647100_ofag383-B22","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/S1473-3099(24)00289-5","article-title":"Switch to long-acting cabotegravir and rilpivirine in virologically suppressed adults with HIV in Africa (CARES): week 48 results from a randomised, multicentre, open-label, non-inferiority trial","volume":"24","author":"Kityo","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"2026092901212647100_ofag383-B23","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1056\/NEJMoa1909512","article-title":"Long-acting cabotegravir and rilpivirine after oral induction for HIV-1 infection","volume":"382","author":"Orkin","year":"2020","journal-title":"N Engl J Med"},{"key":"2026092901212647100_ofag383-B24","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1016\/S0140-6736(20)32666-0","article-title":"Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study","volume":"396","author":"Overton","year":"2021","journal-title":"Lancet"},{"key":"2026092901212647100_ofag383-B25","doi-asserted-by":"crossref","first-page":"e566","DOI":"10.1016\/S2352-3018(23)00136-4","article-title":"Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trial","volume":"10","author":"Ramgopal","year":"2023","journal-title":"Lancet HIV"},{"key":"2026092901212647100_ofag383-B26","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1007\/s40121-023-00890-2","article-title":"Cabotegravir + rilpivirine long-acting injections for HIV treatment in the US: real world data from the OPERA cohort","volume":"12","author":"Sension","year":"2023","journal-title":"Infect Dis Ther"},{"key":"2026092901212647100_ofag383-B27","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1056\/NEJMoa1904398","article-title":"Long-acting cabotegravir and rilpivirine for maintenance of HIV-1 suppression","volume":"382","author":"Swindells","year":"2020","journal-title":"N Engl J Med"},{"key":"2026092901212647100_ofag383-B28","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s40271-021-00524-0","article-title":"Patient-reported outcomes through 1 year of an HIV-1 clinical trial evaluating long-acting cabotegravir and rilpivirine administered every 4 or 8 weeks (ATLAS-2M)","volume":"14","author":"Chounta","year":"2021","journal-title":"Patient"},{"key":"2026092901212647100_ofag383-B29","doi-asserted-by":"crossref","first-page":"3533","DOI":"10.1007\/s10461-020-02929-8","article-title":"Patient-reported outcomes in ATLAS and FLAIR participants on long-acting regimens of cabotegravir and rilpivirine over 48 weeks","volume":"24","author":"Murray","year":"2020","journal-title":"AIDS Behav"},{"key":"2026092901212647100_ofag383-B30","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1093\/cid\/ciae523","article-title":"Perspectives of people with HIV on implementing long-acting cabotegravir plus rilpivirine in clinics and community settings in the United Kingdom: results from the antisexist, antiracist, antiageist implementing long-acting novel antiretrovirals study","volume":"80","author":"Orkin","year":"2025","journal-title":"Clin Infect Dis"},{"key":"2026092901212647100_ofag383-B31","first-page":"559","article-title":"2022 update of the drug resistance mutations in HIV-1","volume":"30","author":"Wensing","year":"2022","journal-title":"Top Antivir Med"},{"key":"2026092901212647100_ofag383-B32","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciag435","article-title":"Impact of HIV-1 RNA selection on low-level viremia and clinical trial endpoint interpretations","author":"Geretti","year":"2026","journal-title":"Clin Infect Dis"},{"key":"2026092901212647100_ofag383-B33","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(18)32462-0","article-title":"Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials","volume":"393","author":"Cahn","year":"2019","journal-title":"Lancet"},{"key":"2026092901212647100_ofag383-B34","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1093\/cid\/ciaf415","article-title":"Efficacy and safety of dual therapy with dolutegravir\/lamivudine in treatment-naive persons with CD4 counts &lt;200\/mm3: 48-week results of the DOLCE study","volume":"82","author":"Figueroa","year":"2025","journal-title":"Clin Infect Dis"},{"key":"2026092901212647100_ofag383-B35","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1097\/QAD.0000000000002979","article-title":"Dolutegravir\/lamivudine as a first-line regimen in a test-and-treat setting for newly diagnosed people living with HIV","volume":"35","author":"Rolle","year":"2021","journal-title":"AIDS"},{"key":"2026092901212647100_ofag383-B36","author":"Underwood"},{"key":"2026092901212647100_ofag383-B37","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s12916-016-0640-4","article-title":"Beyond viral suppression of HIV\u2014the new quality of life frontier","volume":"14","author":"Lazarus","year":"2016","journal-title":"BMC Med"},{"key":"2026092901212647100_ofag383-B38","author":"UNAIDS"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofag383\/70021884\/ofag383.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/13\/9\/ofag383\/70021884\/ofag383.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/13\/9\/ofag383\/70021884\/ofag383.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T05:21:36Z","timestamp":1790659296000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofag383\/8741827"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,25]]},"references-count":38,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofag383","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9]]},"published":{"date-parts":[[2026,7,25]]},"article-number":"ofag383"}}